Impact of persistent minimal residual disease post‐consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report

Summary Patient‐specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French‐British‐American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) wa...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2015-08, Vol.170 (3), p.367-371
Main Authors: Shiramizu, Bruce, Goldman, Stanton, Smith, Lynette, Agsalda‐Garcia, Melissa, Galardy, Paul, Perkins, Sherrie L., Frazer, J. Kimble, Sanger, Warren, Anderson, James R., Gross, Thomas G., Weinstein, Howard, Harrison, Lauren, Barth, Matthew J., Mussolin, Lara, Cairo, Mitchell S.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Burkitt Lymphoma - blood
Burkitt Lymphoma - drug therapy
central nervous system
Central Nervous System Neoplasms - blood
Central Nervous System Neoplasms - drug therapy
Child
Child, Preschool
children
Consolidation Chemotherapy
Female
Humans
leukaemia
Male
Neoplasm, Residual
Pilot Projects
Real-Time Polymerase Chain Reaction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Patient‐specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French‐British‐American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real‐time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD‐positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.13443